Completion of subscription of convertible loans
07 Febbraio 2024 - 1:38PM
UK Regulatory
Completion of subscription of convertible loans
7 February 2024
Company Announcement No. 05
Completion of subscription of convertible
loans
On 7 February 2024 the Board of Directors in
Pharma Equity Group decided to issue convertible loans in
accordance with the authorisation in the company's articles of
association under article 4.3.A.
The convertible loans are now fully subscribed
for and allow Pharma Equity Group to loan DKK 7.100.000, where
6.600.000 has now been paid out to the Company. Thus, the maximum
increase of the share capital pursuant to the convertible loan is
an amount of DKK 10.407.806.
The main terms are described in the company’s
articles of association and Company Announcement no. 04, dated 7
February 2024.
The Board of Directors will inform the market
about conversion of the convertible debt.
For further information, please
contact:
Thomas Kaas Selsø, CEO of Pharma Equity Group
A/S, phone: +45 4022 2114
Christian Vinding Thomsen, Chairman of the Board
of Directors of Pharma Equity Group A/S, phone: +45 2622 7222
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing
extensive support, resources, and expertise to drive the
development and success of these projects. As a strategic partner,
Pharma Equity Group works closely with Reponex Pharmaceuticals,
prioritizing the advancement of innovative medical solutions and
breakthrough therapies. Every effort is currently directed towards
ensuring the utmost success and impact of Reponex Pharmaceuticals'
medical projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open to new
strategic investments for continuous growth.
- 2024 02 07 - Announcement no 05 - UK
Grafico Azioni Pharma Equity Group A/s (LSE:0REU)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Pharma Equity Group A/s (LSE:0REU)
Storico
Da Gen 2024 a Gen 2025
